Scholars Central

Conference abstractPublished 2018

Interchangeability: Can this be established without switching clinical trial?

Authors: Rafiq Islam

Celerion Inc., U

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The Biologics Price competition and Innovation Act of 2009 (BPCIA) created an abbreviated pathway for the FDA licensure of biologics that are “biosimilar” or “interchangeable” to a USA-approved reference product. . Under the act, and based on subsequent FDA guidances, a biosimilar is defined as a biologic that is highly similar to the reference product, and there are no clinically meaningful differences between the two products in terms of safety, purity and potency. A biosimilar is considered interchangeable if it can be expected to produce the same clinical result as the reference product. It is also expected that the risk, in terms of safety or diminished efficacy, of switching the two products in the same patient is no greater than when administering the reference product without switching. It should be noted that only an interchangeable product may be substituted for the reference product without the intervention of the prescribing health care provider. As the name of BPCIA suggests, the original intent of this regulation was to spur innovation which in turn will and help bring these life-saving biologics to market quickly and in a cost-effective manner. Reviews of the approaches used for currently approved biosimilars suggest that most manufacturers utilize traditional technologies and processes to bring these drugs to market. The result is a long approval time and modest savings. In order to realize the true benefit from biosimilar or interchangeable products, we need innovation. We also need, as stated by Dr. Steven Kozlowski, M.D. Director, Office of Biotechnology Products, FDA, “cultural and cognitive transformation.” This presentation will make a case for using fingerprinting-like biosimilarity tool combined with a predictive immunogenicity solution using state of the art data modeling to demonstrate the interchangeability of an approved biosimilars product without any additional clinical trial. A case study using bevacizumab will be utilized to demonstrate biosimilarity and interchangeability.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Nephrology & Renal Diseases.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Nephrology & Renal Diseases
  • SubjectNephrology & Urology
  • BylineArticles whose byline prints “Rafiq Islam”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels